Radar snapshot

26
Products tracked
2
Fringe signals
5
Segments

Highest velocity signals this month

Bemotrizinol: the first US launch shipped August 31, 2026. The exclusivity clock is running.
Oral phenylephrine: final order still unpublished. Effervescent bitartrate gets a narrow monograph path.
GLP-1 claims: the FTC applies the same substantiation standard to telehealth and OTC-adjacent brands.
Rextovy: the third naloxone Rx-to-OTC switch, approved June 16, 2026.

Current alerts

AmberOral phenylephrine final order still pending
AmberGLP-1 companion claims substantiation gap
SignalBemotrizinol on US shelves, launched August 31, 2026
SignalEffervescent phenylephrine bitartrate monograph path
SignalOMUFA II funding secured through FY2030

This edition

2 radar position changes: bemotrizinol, oral phenylephrine. 1 new entry: effervescent phenylephrine bitartrate
0 red alerts. 1 new green signal: effervescent PEB monograph amendment. Bemotrizinol updated to the actual launch date
1 white space updated: bemotrizinol timing now runs from the August 31, 2026 launch